Cessatech A/S — Investor Relations & Filings

Cessatech A/S is a pivotal-stage biotech company focused on developing and commercializing medicines for children. The company's strategy involves repositioning well-known drugs into child-friendly formulations and delivery methods, which reduces development risk and accelerates time to market. Its primary area of focus is addressing significant unmet needs in paediatric acute pain management, particularly in hospital and emergency settings. The lead asset, CT001, is a non-invasive analgesic nasal spray designed for children aged 1-17 experiencing acute pain or pain related to medical procedures. This product provides an alternative to intravenous solutions that can be difficult to administer to young patients. Cessatech aims to grow through strategic partnerships that support regulatory processes and commercialization in key markets.